Etanercept (Enbrel®) alternative storage at ambient temperature.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Clinical Pharmacology : Advances and Applications Pub Date : 2017-07-21 eCollection Date: 2017-01-01 DOI:10.2147/CPAA.S131832
Edel Shannon, Joanne Daffy, Heather Jones, Andrea Paulson, Steven M Vicik
{"title":"Etanercept (Enbrel<sup>®</sup>) alternative storage at ambient temperature.","authors":"Edel Shannon, Joanne Daffy, Heather Jones, Andrea Paulson, Steven M Vicik","doi":"10.2147/CPAA.S131832","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors such as etanercept (Enbrel<sup>®</sup>), have improved outcomes for patients with rheumatic and other inflammatory diseases, with sustained remission being the optimal goal for patients with rheumatoid arthritis. Flexible and convenient treatment options, compatible with modern lifestyle, are important in helping patients maintain treatment and manage their disease. Etanercept drug product (DP) is available in lyophilized powder (Lyo) for solution injection, prefilled syringe, and prefilled pen presentations and is typically stored under refrigerated conditions. We aimed to generate a comprehensive analytical data package from stability testing of key quality attributes, consistent with regulatory requirements, to determine whether the product profile of etanercept is maintained at ambient temperature.</p><p><strong>Methods: </strong>Test methods assessing key attributes of purity, quality, potency, and safety were performed over time, following storage of etanercept DP presentations under a range of conditions.</p><p><strong>Results: </strong>Results and statistical analysis from stability testing (based on size exclusion high-performance liquid chromatography, hydrophobic interaction chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis Coomassie) across all etanercept presentations (10 and 25 mg/vial Lyo DP; 25 and 50 mg prefilled syringe DP; 50 mg prefilled pen DP) showed key stability-indicating parameters were within acceptable limits through the alternative storage condition of 25°C±2°C for 1 month.</p><p><strong>Conclusion: </strong>Stability testing performed in line with regulatory requirements supports a single period of storage for etanercept DP at an alternative storage condition of 25°C±2°C for up to 1 month within the approved expiry of the product. This alternative storage condition represents further innovation in the etanercept product lifecycle, providing greater flexibility and enhanced overall convenience for patients.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":"9 ","pages":"87-99"},"PeriodicalIF":3.1000,"publicationDate":"2017-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/00/8b/cpaa-9-087.PMC5531722.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S131832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Biologic disease-modifying antirheumatic drugs, including tumor necrosis factor inhibitors such as etanercept (Enbrel®), have improved outcomes for patients with rheumatic and other inflammatory diseases, with sustained remission being the optimal goal for patients with rheumatoid arthritis. Flexible and convenient treatment options, compatible with modern lifestyle, are important in helping patients maintain treatment and manage their disease. Etanercept drug product (DP) is available in lyophilized powder (Lyo) for solution injection, prefilled syringe, and prefilled pen presentations and is typically stored under refrigerated conditions. We aimed to generate a comprehensive analytical data package from stability testing of key quality attributes, consistent with regulatory requirements, to determine whether the product profile of etanercept is maintained at ambient temperature.

Methods: Test methods assessing key attributes of purity, quality, potency, and safety were performed over time, following storage of etanercept DP presentations under a range of conditions.

Results: Results and statistical analysis from stability testing (based on size exclusion high-performance liquid chromatography, hydrophobic interaction chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis Coomassie) across all etanercept presentations (10 and 25 mg/vial Lyo DP; 25 and 50 mg prefilled syringe DP; 50 mg prefilled pen DP) showed key stability-indicating parameters were within acceptable limits through the alternative storage condition of 25°C±2°C for 1 month.

Conclusion: Stability testing performed in line with regulatory requirements supports a single period of storage for etanercept DP at an alternative storage condition of 25°C±2°C for up to 1 month within the approved expiry of the product. This alternative storage condition represents further innovation in the etanercept product lifecycle, providing greater flexibility and enhanced overall convenience for patients.

Abstract Image

Abstract Image

Abstract Image

Etanercept (Enbrel®) 可选择在环境温度下储存。
背景:包括依那西普(Enbrel®)等肿瘤坏死因子抑制剂在内的生物改变病情抗风湿药改善了风湿病和其他炎症性疾病患者的治疗效果,而持续缓解是类风湿性关节炎患者的最佳目标。灵活方便、符合现代生活方式的治疗方案对于帮助患者维持治疗和控制病情非常重要。Etanercept 药物产品(DP)有溶液注射用冻干粉(Lyo)、预灌封注射器和预灌封笔三种剂型,通常在冷藏条件下储存。我们的目标是根据监管要求,从关键质量属性的稳定性测试中生成一个全面的分析数据包,以确定依那西普是否能在环境温度下保持产品特性:方法:在各种条件下储存依那西普(etanercept)DP制剂后,随时间推移对纯度、质量、效力和安全性等关键属性进行评估:结果:所有依那西普制剂(10和25毫克/瓶Lyo DP;25和50毫克预充式注射器DP;50毫克预充式笔DP)的稳定性测试结果和统计分析(基于尺寸排阻高效液相色谱法、疏水相互作用色谱法和十二烷基硫酸钠-聚丙烯酰胺凝胶电泳Coomassie)表明,在25°C±2°C的替代储存条件下储存1个月,关键的稳定性指示参数在可接受范围内:根据法规要求进行的稳定性测试表明,在产品的批准有效期内,etanercept DP 可在 25°C±2°C 的替代储存条件下储存 1 个月。这种替代储存条件代表了依那西普产品生命周期的进一步创新,为患者提供了更大的灵活性和更多的便利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
0.00%
发文量
14
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信